PMID- 32733250
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Chijabyukpi-Tang Inhibits Pro-Inflammatory Cytokines and Chemokines via the 
      Nrf2/HO-1 Signaling Pathway in TNF-alpha/IFN-gamma-Stimulated HaCaT Cells and Ameliorates 
      2,4-Dinitrochlorobenzene-Induced Atopic Dermatitis-Like Skin Lesions in Mice.
PG  - 1018
LID - 10.3389/fphar.2020.01018 [doi]
LID - 1018
AB  - Chijabyukpi-tang (CBT) is an oriental herbal formula consisting of three herbs 
      (Gardeniae Fructus (Gardenia jasminoides J.Ellis.), Phellodendri Cortex 
      (Phellodendron amurense Rupr.), Glycyrrhizae Radix (Glycyrrhiza uralensis Fisch. 
      ex DC.) at the ratio of 2: 2: 1. CBT has traditionally been used to treat eczema 
      with inflammation in Northeast Asia. The components of CBT have been shown to 
      have anti-inflammatory and anti-oxidant properties, but the exact role and 
      mechanism of CBT on atopic dermatitis (AD) remain unclear. In this study, we 
      investigated the anti-inflammatory effect and mechanism of CBT in the HaCaT human 
      keratinocyte cell line and investigated the anti-atopic effect in mice models of 
      atopic dermatitis-like skin lesions. In the tumor necrosis factor alpha 
      (TNF)-alpha/interferon (IFN)-gamma-stimulated HaCaT cells, CBT inhibited the production 
      of pro-inflammatory cytokines and chemokines and elevated the nuclear 
      translocation of NF-E2 p45 related factors 2 (Nrf2) and subsequent production of 
      heme oxygenase-1 (HO-1). CBT improved the symptoms of atopic dermatitis-like 
      lesions in 2,4-dinitrochlorobenzene (DNCB)-treated mice by suppressing the levels 
      of serum immunoglobulin E (IgE), and various pro-inflammatory cytokines and 
      chemokines. The improvement effect of CBT on atopic dermatitis-like lesions can 
      be predicted to be due to increased Nrf2 and HO-1 gene expression. These results 
      suggest that CBT is an herbal medicine with the potential for use as a 
      therapeutic agent for inflammatory skin diseases such as atopic dermatitis.
CI  - Copyright (c) 2020 Lee, Lim, Jo, Noh, Park, Park and Kim.
FAU - Lee, Ji-Hyun
AU  - Lee JH
AD  - Department of Immunology and Institute of Medical Sciences, Medical School, 
      Chonbuk National University, Jeonju, South Korea.
FAU - Lim, Ji-Ye
AU  - Lim JY
AD  - Department of Immunology and Institute of Medical Sciences, Medical School, 
      Chonbuk National University, Jeonju, South Korea.
FAU - Jo, Eun Hee
AU  - Jo EH
AD  - Research Center of Traditional Korean Medicine, Wonkwang University, Iksan, South 
      Korea.
AD  - Department of Acupuncture and Moxibustion, College of Korean Medicine, Wonkwang 
      University, Iksan, South Korea.
FAU - Noh, Hyeon Min
AU  - Noh HM
AD  - Korean Traditional Medicine Institute, Wonkwang University, Iksan, South Korea.
FAU - Park, Sunggu
AU  - Park S
AD  - Department of Korean Medical Ophthalmology & Otolaryngology & Dermatology, 
      College of Korean Medicine, Wonkwang University, Iksan, South Korea.
FAU - Park, Min Cheol
AU  - Park MC
AD  - Research Center of Traditional Korean Medicine, Wonkwang University, Iksan, South 
      Korea.
AD  - Department of Korean Medical Ophthalmology & Otolaryngology & Dermatology, 
      College of Korean Medicine, Wonkwang University, Iksan, South Korea.
FAU - Kim, Dae-Ki
AU  - Kim DK
AD  - Department of Immunology and Institute of Medical Sciences, Medical School, 
      Chonbuk National University, Jeonju, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20200707
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7358535
OTO - NOTNLM
OT  - Chijabyukpi-tang
OT  - atopic dermatitis
OT  - chemokine
OT  - cytokine
OT  - inflammation
OT  - keratinocytes
EDAT- 2020/08/01 06:00
MHDA- 2020/08/01 06:01
PMCR- 2020/07/07
CRDT- 2020/08/01 06:00
PHST- 2019/12/04 00:00 [received]
PHST- 2020/06/23 00:00 [accepted]
PHST- 2020/08/01 06:00 [entrez]
PHST- 2020/08/01 06:00 [pubmed]
PHST- 2020/08/01 06:01 [medline]
PHST- 2020/07/07 00:00 [pmc-release]
AID - 10.3389/fphar.2020.01018 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Jul 7;11:1018. doi: 10.3389/fphar.2020.01018. eCollection 
      2020.